Patents by Inventor John Janusz

John Janusz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating anemia
    Patent number: 12569474
    Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: March 10, 2026
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner
  • Compositions, formulations and methods for treating ocular diseases
    Patent number: 12152023
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: November 26, 2024
    Assignee: EYEPOINT PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • COMPOSITIONS AND METHODS FOR TREATING ANEMIA
    Publication number: 20240335434
    Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
    Type: Application
    Filed: November 16, 2023
    Publication date: October 10, 2024
    Inventors: Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner
  • METHODS FOR MANUFACTURE OF SMALL MOLECULE ACTIVATORS OF TIE-2
    Publication number: 20240190857
    Abstract: Disclosed herein are compounds effective for modulation of Tie-2 activity and inhibition of HPTP-beta, and methods of preparation thereof. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neovascularization.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 13, 2024
    Inventors: John JANUSZ, Jared RANDALL, James COPP
  • Compositions and methods for treating anemia
    Patent number: 11857543
    Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: January 2, 2024
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20220274976
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: March 3, 2022
    Publication date: September 1, 2022
    Inventors: Kevin PETERS, Robert SHALWITZ, John JANUSZ, Alexander SMITH
  • HPTP-BETA INHIBITORS
    Publication number: 20210130341
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Application
    Filed: October 2, 2020
    Publication date: May 6, 2021
    Inventors: John Janusz, James Copp, Kevin Peters
  • HPTP-Beta inhibitors
    Patent number: 10858354
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 8, 2020
    Assignee: Aerpio Pharmaceuticals, Inc.
    Inventors: John Janusz, James Copp, Kevin Peters
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20200361926
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: May 29, 2020
    Publication date: November 19, 2020
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • HPTP-BETA INHIBITORS
    Publication number: 20180354937
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Application
    Filed: May 7, 2018
    Publication date: December 13, 2018
    Inventors: John Janusz, James Copp, Kevin Peters
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20180251457
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: May 2, 2018
    Publication date: September 6, 2018
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20180237429
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 23, 2018
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20180237431
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 23, 2018
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20180237430
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 23, 2018
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • HPTP-? inhibitors
    Patent number: 9994560
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 12, 2018
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: John Janusz, James Copp, Kevin Peters
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20180022741
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: February 27, 2017
    Publication date: January 25, 2018
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • Compositions, formulations and methods for treating ocular diseases
    Patent number: 9440963
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 13, 2016
    Assignee: AERPIO THERAPEUTICS, INC.
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20160220541
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 4, 2016
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
    Publication number: 20160220540
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 4, 2016
    Inventors: Kevin Peters, Robert Shalwitz, John Janusz, Alexander Smith
  • COMPOSITIONS AND METHODS FOR TREATING ANEMIA
    Publication number: 20160143891
    Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
    Type: Application
    Filed: June 4, 2014
    Publication date: May 26, 2016
    Applicant: Akebia Therapeutics, Inc.
    Inventors: Robert Shalwitz, Charlotte Hartman, Akshay Buch, Isaiah Shalwitz, John Janusz, Joseph Gardner